{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T09:45:14Z","timestamp":1785059114313,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,21]]},"DOI":"10.7759\/cureus.97410","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:04:56Z","timestamp":1763726696000},"source":"Crossref","is-referenced-by-count":2,"title":["An Online Prescription for Hospitalisation: Euglycaemic Ketoacidosis Caused by an Online Tirzepatide Prescription"],"prefix":"10.7759","author":[{"given":"Thibagaran","family":"Sathambihai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kushagra","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seshnag","family":"Siddavaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Obesity Statistic","author":"Steibahl S","year":"2025","unstructured":"Steibahl S. Obesity Statistic. House of Commons Library, 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref3","unstructured":"Tirzepatide for managing overweight and obesity. (2024). Accessed. October 24, 2025: https:\/\/www.nice.org.uk\/guidance\/ta1026\/chapter\/1-Recommendations."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne LJ","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al.. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024, 331:38-48. 10.1001\/jama.2023.24945","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne LJ","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al.. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025, 393:26-36. 10.1056\/NEJMoa2416394","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2023.2277337","article-title":"Tirzepatide-associated starvation ketoacidosis","volume":"61","author":"Mercer J","year":"2023","unstructured":"Mercer J, Lipscomb J, Lipscomba J, Gao HT, King K. Tirzepatide-associated starvation ketoacidosis. Clin Toxicol (Phila). 2023, 61:1064-5. 10.1080\/15563650.2023.2277337","journal-title":"Clin Toxicol (Phila)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu QK","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024, 15:1431292. 10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hch064","article-title":"An unusual cause for ketoacidosis","volume":"97","author":"Davids MR","year":"2004","unstructured":"Davids MR, Segal AS, Brunengraber H, et al.. An unusual cause for ketoacidosis. QJM. 2004, 97:365-76. 10.1093\/qjmed\/hch064","journal-title":"QJM"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf028","article-title":"Euglycemic ketoacidosis following coadministration of an SGLT2 inhibitor and tirzepatide","volume":"3","author":"Louwagie EJ","year":"2025","unstructured":"Louwagie EJ, Diego JN, Farooqi CS, Kamal MM. Euglycemic ketoacidosis following coadministration of an SGLT2 inhibitor and tirzepatide. JCEM Case Rep. 2025, 3:luaf028. 10.1210\/jcemcr\/luaf028","journal-title":"JCEM Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004357","article-title":"Tirzepatide-induced ketoacidosis in non-diabetic patients","volume":"11","author":"Iqbal PMR","year":"2024","unstructured":"Iqbal PMR, Maadarani OS, Bitar ZI. Tirzepatide-induced ketoacidosis in non-diabetic patients. Eur J Case Rep Intern Med. 2024, 11:4357. 10.12890\/2024_004357","journal-title":"Eur J Case Rep Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434920-an-online-prescription-for-hospitalisation-euglycaemic-ketoacidosis-caused-by-an-online-tirzepatide-prescription","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:04:57Z","timestamp":1763726697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434920-an-online-prescription-for-hospitalisation-euglycaemic-ketoacidosis-caused-by-an-online-tirzepatide-prescription"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.97410","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,21]]}}}